Histoplasma capsulatum: Difference between revisions
From IDWiki
Histoplasma capsulatum
m (Aidan moved page Dimorphic Histoplasma capsulatum to Histoplasma capsulatum without leaving a redirect) |
No edit summary |
||
Line 1: | Line 1: | ||
⚫ | |||
== Microbiology == |
== Microbiology == |
||
Line 197: | Line 195: | ||
'''Source:''' IDSA guidelines 2007 |
'''Source:''' IDSA guidelines 2007 |
||
⚫ | |||
[[Category:Dimorphic fungi]] |
Revision as of 23:22, 14 August 2019
Microbiology
- Dimorphic fungus; mold at room temperature, yeast at >37º C
- Mold: aerial hyphae with macroconidia
- Mold form is highly infectious, associated with lab-related outbreaks
- Mycelia have a typical appearance of spiked spherical conidia
- Yeast:
- Non-infectious, once hanging out in your body
- Narrow-based budding
- Mold: aerial hyphae with macroconidia
- H. capsulatum var. capsulatum most common worldwide, in various clades
- H. capsulatum var. duboisii present in western Africa, has larger yeast forms
- Can take up to 7 days to grow
Epidemiology
- Endemic in many parts of the world
- Ohio and Mississippi River Valley systems (Central/Eastern US)
- Probably up through St. Lawrence River as well
- Probably more broadly distributed, including Central and South America, South and East Asia, and Australia
- H. capsulatum var. duboisii in western Africa
- Typically found in moist soil enriched with bat or bird droppings, which helps it to sporulate
- Disturbing the soil aerosolizes it, allowing the microconidia to be inhaled
Histoplasmosis map from https://doi.org/10.1007/s40475-015-0044-0
Pathophysiology
- Inhaled microconidia reach the alveolii and are phagocytosed by alveolar macrophages
- Innoculum size can be smaller with immunodeficiency
- Size of innoculation affects disease severity and progression
- Microconidia transform into budding yeasts, in a process that is dependent on macrophage calcium and iron
- They multiply inside macrophages, and translocate through the lymphatics
- Cellular immunity developed around 2 weeks later
- Response depends on IL-12 and TNF-alpha
- Organize to form granulomas to contain the infection
- Latent infection can reactivate, but rare
- Most common with infliximab
- In impaired cellular immunity, infection can become disseminated
Clinical Presentation
- Often asymptomatic; in endemic areas, 50-80% of people skin-test positive or have radiographic evidence of previous infection
- Can cross tissue planes
Acute pulmonary histoplasmosis
- Fever, chill, malaise, headaches, myalgias, anorexia, cough, dyspnea, and chest pain
- Pneumonitis on chest x-ray, often with adenopathy
- "Buckshot" appearance? (Mandell)
- Can have rheumatologic sequelae in 5-10%, with arthralgias, arthritis, and erythema nodosum
- Can have pericarditis from the inflammatory response
- Hilar adenopathy can necrotize
- Usually self-limited, no need to treat unless longer than a month
Progressive disseminated histoplasmosis
- Usually, though not exclusively, in immunocompromised pations
- Risk factors include CD4 <200, very old or very young, and therapeutic immunosuppression (pred, MMF, tac, MTX, TNF-alpha, other biologics
- Can be rapidly-progressing and acute, or more subacute
Acute progressive disseminated histoplasmosis
- Fever, weight loss, organomegaly, thrombocytopenia
- Meningitis or focal brain lesions
- Oral and GI mucosal ulcerations
- Adrenal insufficiency
Chronic progressive disseminated histoplasmosis
- In normal hosts
- Absent or low-grade fever
- Longer course
- Most common finding is oropharyngeal lesion: deep, well-circumscribed, unrated, and painless
- Mimics squamous cell carcinoma
- Can also have hepatosplenomegaly, chronic meningitis, or chronic granulomatous hepatitis
Chronic cavitary histoplasmosis
- Typically seen in bullous emphysema
- Productive cough, dyspnea, low-grade fever, night sweats, weight loss
- Hemoptysis is rare
- Progressive without treatment
- Chest x-ray shows upper-lobe infiltrations, vacitation, and pleural thickening, similar to tuberculosis
Fibrosing mediastinitis
- Rare but serious
- Progressive fibrosis around hilar/mediatinal lymphadenopathy, wither unilateral or bilateral
- Can present with a SVC syndrome, obstruction of pulmonary vessels, or airway obstruction
- Can also present with recurrent pneumonias, hemoptysis, or respiratory failure
- 30% mortality
Other complications
- Ophthalmic uveitis
- Meningitis
- Endocarditis
African histoplasmosis
- H. capsulatum vars. capsulatum and duboisii coexist in Africa
- var. duboisii has more skin and skeletal manifestations
- Ulcers, nodules, or psoriaform lesions that can spontaneously resolve
- Can cause a cold abscess, without inflammation
- Osteolytic bone lesions are common (50%) of cases
- Skull and ribs most common
- Can have sinus formation and cystic bone lesions
- May not have any evidence on CXR of prior pulmonary histoplasmosis
- Can also present with progressive disseminated disease, with fevers and multiorgan involvement
- Combianation of granulomas and pus
- Larger yeast is harder for macrophages to engulf
- Ulcers, nodules, or psoriaform lesions that can spontaneously resolve
Diagnosis
- Fungal culture of sputum (chronic cavitary), or blood or bone marrow aspirate (disseminated), or CSF (CNS histo)
- Mold and yeast forms depending on the temperature
- Best stain is GMS (Giemsa m…. silver)
- Seen within the macrophages
- Serology can be done for antigen or antibody
- Serology may be negative in immunosuppressed patients
- Antigen of urine (best), BAL fluid, and serum
- Urine is best, but only 40% sensitive in cavitary, up to 95% in AIDS patients
- Cross-reacts with other endemic fungi
- PCR is possible
- 16S PCR
Management
Syndrome | Treatment |
---|---|
Acute pulmonary histoplasmosis | |
Mild, self-resolving | If resolves within a month, no need to treat |
Mild, ongoing symptoms | Itra 200 mg po TID x3d then itra 200 mg po daily or BID for 6-12 weeks |
Moderate to severe | Lipo ampho B 3-5 mg/kg/d for 1-2 weeks then itra 200 mg TID x3d then itra 200 mg BID x12wk Methylpred 0.5-1 mg/kg IV daily for first 1-2 weeks if respiratory complications |
Chronic cavitary pulmonary histoplasmosis | Itra 200 mg TID x3d then daily or BID for at least 1 year (18-24 months may have lower relapse) |
Complications | |
Pericarditis | NSAIDs if mild Pred 0.5-1 mg/kg daily then taper over 1-2 weeks, plus itra (as above) for 6-12 weeks if hemodynamic compromise May need therapeutic pericardiocentesis |
Rheumatologic | NSAIDs if mild, prednisone and itraconazole (as for pericarditis) if severe |
Mediastinal lymphadenitis | Usually no treatment. Follow guide for acute pulmonary histoplasmosis. |
Mediastinal granuloma | Usually no treatment. Standard itra protocol for 6-12 weeks if symptomatic. |
Mediastinal fibrosis | Antifungals not recommended. Treat only if there is suspicion of mediastinal granuloma. May need stenting of obstructed pulmonary vessels. |
Broncholithiasis | Antifungals not recommended. May need surgery. |
Progressive disseminated histoplasmosis | Follow antigen levels during therapy and for 12 months after to monitor for relapse |
Mild to moderate | Itraconazole for 12 months |
Moderately severe to severe | Lipo ampho B 3 mg/kg for 1-2 weeks then oral itraconazole for at least 12 months |
Immunosuppressed | May need lifelong suppressive therapy with itra 200 mg po daily |
CNS histoplasmosis | Lipo ampho B 5 mg/kg daily for 4-6 weeks (total 175 mg/kg) followed by itraconazole for at least 1 year, until resolution of CSF abnormalities |
Pregnancy | Lipo ampho B 3-5 mg/kg for 4-6 weeks |
Children | As per above guidelines, with ampho B deoxy 1 mg/kg and itra 2.5-5 mg/kg bid (max 400 mg daily) |
Prophylaxis | Itra 200 mg po daily recommended if HIV with CD4 <150 and more than 10 cases per 100 patient-years |
Note: therapeutic drug level monitoring is recommended for itraconazole
Source: IDSA guidelines 2007